Impact of immature haematopoetic cells on clinical risk stratification of patients with coagulation inhibitor therapy

Impact of immature haematopoetic cells on clinical risk stratification of patients with coagulation inhibitor therapy - PRISCA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028143

Enrollment

15000

Registered

2022-03-11

Start date

2022-02-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiolgical, angiological, heart and vascular surgical interventions

Interventions

Group 1: IPF and RetHE at the time of intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Intra hospital therapy at the University Heart Center Freiburg - Bad Krozingen, Campus Bad Krozingen between 01/07/2020 and 31/12/2021.

Exclusion criteria

Exclusion criteria: - missing follow-up data - missing laboratory values - patients, working at the university heart center - patients with relevant psychiatrc desease or relevant reduced mental status

Design outcomes

Primary

Measure	Time frame
- Bleeding complications defined as BARC =2 - ischemic events (cardiovascular death, non-fatal myocardial infarction, stroke)	—

Secondary

Measure	Time frame
- death - non-fatal myocardial infarction - stroke - thrombembolism (every location) - peripheral vassel occlusion and/or peripheral ischemia	—

Countries

Germany

Contacts

Public ContactAlexander Kille

Universitätsherzzentrum

alexander.kille@uniklinik-freiburg.de07633 402 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026